Skip to main content

What AbbVie's Quarter ended Sep 30, 2026 10-Q says: 4 signals

AbbVie filed its latest 10-Q with the SEC on Nov 3, 2026. It discusses acquisition completed, AI investment and litigation material.

Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn

Get AbbVie's live signals in Claude or ChatGPT, or by API

AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.
Filed
Nov 3, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
13

Source: Autobound Signal API · 112 signals tracked for AbbVie · updated

10-Q · latest 10

What AbbVie's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 5 signals

    SEC EDGAR

Showing 10 of 13 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

AbbVie earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Net revenues reach $17.4B, up 10.5% operational growthAbbVie delivered $17.4 billion in Q3 2026 total net revenues, beating guidance by $200 million and delivering 10.5% operational growth. Nine key commercial products delivered double-digit growth, driving strong operating cash flow and high vendor evaluation capacity.
IRA price negotiation and 340B discounts pressure drug revenuesImbruvica revenues dropped 26.1% due to Medicare IRA pricing and competitive pressure, while broader 340B hospital program growth creates persistent pricing headwinds. AbbVie is participating in a 340B rebate pilot for Imbruvica, Linzess, and Vraylar to curb perceived program abuse.
Partnership with Genmab advances Epkinly in frontline lymphomaAbbVie is collaborating with Genmab on Epkinly, booking profit share in the U.S., Puerto Rico, and Japan. Regulatory submissions for frontline DLBCL are planned for early next year following positive Phase III results reducing risk of disease progression or death by 51%.
Expansion into dermatology sales forces for vitiligo and alopeciaAbbVie is building out dedicated dermatology commercial sales forces globally to support anticipated U.S. approvals and European launches for Rinvoq in vitiligo and alopecia areata. Management projects these two new indications will generate nearly $2 billion in peak sales.
Biosimilar competition reduces global Humira sales by 30.6%Global Humira sales fell 30.6% operationally to $683 million as biosimilar erosion continues to impact market share. The ongoing erosion reinforces the company's transition to newer immunology assets Skyrizi and Rinvoq.
Aesthetics segment pressured by economic uncertainty and dermal filler headwindsGlobal aesthetics revenue dropped 1.8% to nearly $1.2 billion, driven by an 11.8% operational decline in Juvéderm sales. Management cited lower consumer confidence and macro pressures on elective procedures, though early signs of stabilization are emerging.

Signal API · MCP

Track AbbVie with the Signal API

One POST /v1/companies/enrich call with abbvie.com returns AbbVie 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about AbbVie 10-Q

When did AbbVie file its latest 10-Q?
AbbVie filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 3, 2026. The one before it was filed on Aug 3, 2026.
What did AbbVie disclose in its latest 10-Q?
From the filing dated Nov 3, 2026: AbbVie announces North Carolina manufacturing campus integrating artificial intelligence and advanced laboratory technologies in 2026
What did AbbVie say on its recent earnings calls?
Q3 FY2026: Net revenues reach $17.4B, up 10.5% operational growth (dated Oct 30, 2026).
Where can I read AbbVie's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →